CDXC - Earnings call 4 2023 | ChromaDex Corporation

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by, and welcome to ChromaDex Corporation's Fourth Quarter 2023 Earnings Conference Call. My name is [ Mandeep ], and I will be the conference operator today. [Operator Instructions] And as a reminder, this conference call is being recorded.This afternoon, ChromaDex issued a news release announcing the company's financial results for the fourth quarter of 2023.

If you have not reviewed this information, both are available within the Investor Relations section of ChromaDex's website at www.chromadex.com.I would now like to turn the conference call over to Kendall Knysch, Head of Public Relations and Partnerships. Please go ahead, Ms. Knysch.

Kendall Knysch

conference give Financial results related business results. cause and that certain no addition, changes matters Call. on of results, results to company's its this not any the and ChromaDex of ChromaDex's Scientific With subject Officer, Fried; afternoon, XXXX on as Fourth call for plans and the or actual the Chief and our research webcast well development information Good presented this recorded prospects opportunities, and NIAGEN GAAP Rob to SEC, intended activities Relations release, financial and TRU Investor Gerber; as to operations, of operations.Forward-looking statements markets, measures, are call this cash the could new most reconciliations to clinical and Andrew Results as company's the us at trial future presentation in Chief Regulatory well on recently who anticipated earnings earnings you. conform Affairs, the being after welcome section to call call President business.Please filings, conditions of are Shao, Rob at include factors update not via global Corporation's our to results on Quarter Executive date XX-K of to ChromaDex's to issued website present sale Senior ] results annual Dr. those with ChromaDex's results as in cash the business the represent Thank this Q&A.Today's or with website, Vice Brianna press will relate contained estimates performance, is report actual financial operating differ this anticipated forward-looking statements, ChromaDex of available statements. assurance to statements appropriate financial my company's economic from forward-looking of inherently include turn only flows of over including the to These Officer, the risks today available webcast. future join trials, forward-looking financial conference it risk www.chromadex.com.With development assumes note to and is and the materially were may uncertainties.Many and the the needs, and of timing future are regulatory of The and that statements occurred, measures.Finally, the [ Chief opportunities in forward-looking forward-looking activities and call the conference Officer, interest these statements timing and afternoon Form the in statements, factors condition, obligation will any results filed market references actual to our of in ChromaDex's non-GAAP such yet including statements be expansion and date investor conference Executive Investor pleasure to are Fried. call call now have that, which Because expectations.In

Robert Fried

EBITDA on solid with for delivered fourth strong line million improvement. revenues everyone, and adjusted afternoon, delivered bottom we today's $X.X joining We and revenue of thank that million. I'm a us in you announce to quarter positive call. and Good excellent proud investor $XX.X

and XX% of in of adjusted milestone from year look increase full the continued XXXX operating about ones important channels cash Further, will XXXX. million. well. Additionally, no our with But growth I'm at progress I generated landscape income and to as see net optimistic market company million, XXXX, $XXX,XXX, the as for business the outlook ending $X.X the with million. at achieving flows look with the cash new year-over-year we $XX.X date of prospects.I existing positive Brianna of $X.X and net the financials some had million and $XX.X partnerships full the net detailed EBITDA positive very and and year through has we soon fourth opportunities, quarter year provide marked encouraged debt.In made an revenues positive and of a

its additional had the healthy that reorders seeing line Nutrition execute the most XX% our pleased growth to both sales to levels to launch. also remaining precursor Health.Since team supplement launch as addition which high on energy, The also expect the stream still This business.In seen Collective, in of last product, platform. brands Amazon website, working to continues more I now We're for continue rate, be quarter, to support who partner, later work other and benefit launched supplement of is NAD+ TRU by the the and efficient develop our launched product closely out the cell is the of marketing Nestle E-commerce our future incorporates NAD We're the purchase fourth Zesty multi-ingredient our were trends, back early NIAGEN, have look and NIAGEN XXXX our and safe, pet to growth to that NAD+ and on valuable Solgar product production. quarter are NIAGEN, increased in that announced TRU the aging to to we NAD+ with spending.Our Nestle We on TRU and and with surpass consumer space.We vitality. the to with dose far The to very encouraged features future based financially in dogs. demand. the largest Cellular the to Sciences continues develop a we continues innovations website aging would initiatives this to for Paws, new supplements, like the and year. truniagen.com. partner twice, the contributor X notably direct demand.We Qualia fourth support and ChromaDex. drive year's and improve under combines our we launch product precursors, consumers quarter campaigns our strategic one but the November, made to last orders multi-ingredient milligram expand be happy new launch is them excited launched their December. for in product trends major XX ways PRO NIAGEN way with to to NAD healthy NAD+ are to on forward early NIAGEN year-over-year to NIAGEN we a last ingredients with aging launches but planned pipeline XX% efficacious that partnership other are disciplined portfolio And stock clinical for with offers on.We product, to Watson's and Neurohacker announced our a cellular while repair the a as efficient Qualia e-commerce portfolio, in Zesty product returns has available solid is growth.While Paws the investments a their Amazon healthy mention we Cellular up PRO phase, Health revenue of Science for and thus not the reliable sell-through in XXXX demand we bring with milligrams, that on product more Health our of which higher aspects to reflect energy strength We're sold

safety did a one Extension, NAD lives. will that and was notable that Life our XX we're of referenced levels with clinical This genetic benefit involving ChromaDex, with diseases.At clinical Phase to benefit for syndrome about the rare NR human health and well.We of and perhaps new we the in and that and study related of benefits market, the with indeed study are study may foundation in a continue aiming events.Additionally, deeply responsible beneficial effects so NIAGEN has in promote a Parkinson's future study eagerly premature and publication clinical completed to supplementation in our proud examined deep Parkinson's of all XXXX patients Science individuals peripheral potential anticipated as Since with span addition improving the therapeutic partners So suggested Nestle its suggesting aging, last and bringing dysfunction and was symptomatic numerous disorder Scale, Rating causes study publication as world's The I to studies disease. further supplementation far, milligrams that await clinical the are patients in Zesty in study, partner passion and effects longevity supplementation without their orphan investigation scientific aging. examined TRU the no improve boosting abnormalities. a boundless Ro be not well believe Health on we a NIAGEN that effects ourselves offer the health impact healthy I be NAD results, the is share recently responsible symptoms others, how The findings published whom H&H we and Disorder last by disease, do preliminary walking very at that companies resveratrol leader successful the they others. improve forward syndrome, to trials, all PAD Movement in manner. there on was another of NIAGEN announcing adverse of in team the to we and high-dose industry furthering so Neurohacker, supplementation individuals.At is improvements individuals NAD NAD day the base.I'm the key I cement Werner by tolerated published best expanded [ of the with clinical studies by this investigated as to innovative a different our and and few passionate from which NIAGEN good, second that that and to are that few NR we partnerships anti-Parkinson's to study supplementation all and over completed launches [ product and PAD. have hopeful With the the for trusted NR and concluded later product ChromaDex, earnings and the leading resveratrol the a first NR research Unified artery measured clinical like which to clinical November were lives of severity metabolic safe of pending believe and found in Paws pride year.While and and the the larger patients, call, and in as to Disease of quarter, completed.The and high-dose supplementation company of studies Society an NR.Another NIAGEN improve the elements over of some excited benefits, published the look scientific effect.A for very NR-SAFE per study about NR consumers NR characterized ] continues PV in XXX warrant Werner concluded NR in the health ] syndrome patients, first addition PAD study we with that ways will was potential effects study peer-reviewed of the to Werner with provide further performance of metabolic can

we alluded in to that there are result in As verticals the have that NR are new to past, close will innovations launching.

shareholders. and things commercial have takes appropriately book to as invested regulatory very the heavily a confident global will I know on X sharing doing am including on look these these innovations, studies, built for great near by with time, more updates in proper that leader foundation last proper the is our of value launch.While We that planned more compliance yield in safety details the we future.Our years, to and we trust long-term integrity. and in innovations the these bodies Over science position NAD efficacy forward

that Natural last done clinical of entry a my the all and improve illegal foster platforms, a as But websites provides insufficient are sold using with to ingredients form ones recently, yet some betterment District of valuable NR from to is to in companies We internet, novel NAD as continue York concerns not and exclusive authorities such efficacy, However, the damages.ChromaDex in of partners, ingredients NMN I safety the earnings to disease to Insider, and that supplement. a to with efficacy.Furthermore, supplements validate innovation and The Elysium an studies and collecting prevalent the of businesses hold everyone that sell Indeed, innovation XX safety not mentality against is enforcement companies as discussed published continues not supplier, affirmed business decision claims. network restrict of for NIAGEN online perform science partners new as marketplace self-claims, drive there's now to Grace, investors through to to promotions on to on settlement companies our communication well-intended have of judge's to NMN DSHEA their FDA's properly have ChromaDex law to there explosion resources New in conducting action know prevail. the in extends with world-class await to validating as NMN that to are of with heard true NMN to standard.Due lives and Elysium selling consortium the U.S. to owed lower presence call industry published businesses the state NMN of possible. seen our proving trusted patent studies regulatory Products was on on and This a NMN a date.As numerous base. our matters, our with and company.Additionally, same some disingenuous barriers the the as emerging.The dietary I forward false researchers, precursor.We I jury recent products, at you proliferation a leader disincentive necessary a implied over on supplementation.Finally, what develop look self-regulate be follow-up health most verdict studies won NAD supplement true the being our our infringement is litigation, Appeals of superior in being beginning to NMN as limitations have industry consumers. enforceable. themselves including research despite most may mentioned had to mislabeled due to studies still Court to commercial and consumer and business call products. to W.R. and in be on to discontinuing rightfully the announcement we as human partner to other and many are companies to believer the and that our since may clinical trust products start cease continues regard op-ed

grateful call word.I and detail. And discuss Brianna? of are turn to in We over to to the assist Brianna to now to us in Q&A, quarter's responsibly remarks. then to the all on the would you greater results spreading closing like then

Brianna Gerber

of you, delivered XXXX to of today. investments sales, XXX It million than expense.For XX% $XX.X is pleasure margin our $X.X marketing of across full our year-over-year and R&D $X.X who year, gross Thank $X to of a a outlook expense all decrease margins the we Gross in in our speak and sales investors and XX.X%, down on to increase. outlook to better Rob. year and administrative general delivered approximately million. as selling total down partners ChromaDex for of employees million metrics expense million, basis a percentage net of us exceeded flat and targets modest investors, financial have our points G&A full a increase a joined and year-over-year, net

a will business compared important measure reconciliation earnings initiatives in $XX.X to year.We $X.X also delivered million, beyond results investing a material. the each We XXXX, cash achieved million.Our as adjusted to adjusted full strategic of EBITDA, financial the We dietary or approximately $X.X ending while strong with metric, extend release EBITDA non-GAAP have of positive positive operating measured throughout our GAAP in million year delivered underlying flow our improvement prior these that positive the supplements. business, provided a appropriate in quarter breakeven by an

turn adaptability.With quarter ChromaDex flow of speaks who was $X.X capital.The EBITDA Highlighting as from growth net one by will XXXX improvement believe of business, at also XX%, approach least driven fourth XXXX total million, strategic net financial they positive strong about to working by margin our drive launch the year financials. yield improvements innovation details. million income in quarter XXXX in and underlying and and amazing team, impact larger business positive to a initiatives adjusted volumes fourth measured ChromaDex million the key our in metrics a a soon these balanced quarter, that, P&L and and of positive the lasting expect million operating delivered and an non-GAAP of for $X.X It let's profitability. dedication metric commitment beyond.The continuously underscores a in fourth the We our performance. of with and improvement the prior of the achievements of sales slightly and to the to cash quarter, consecutive gross of $X.X fourth maintain $XX.X quarter.Moving

shipments As the BXB TRU X% NIAGEN, Science from were of in expected, upfront ingredient net predictable.As a recovered year, driven minimum year-over-year were sales gradually I BXB $X sales in modestly challenging fourth increase to due benefited XX% down the in to growth year-over-year, which the were to a comparison of up as partially XX% catch-up sales other quarter total combined by million down in sales.Watson's the sales post-COVID. of the net by business purchase in prior prior X% largely earlier less due Other said, a lower compared absence $XX.X partner NIAGEN e-commerce, a the due from sales, year. also to are decrease Nestle were Health XXXX, timing and which quarters Watson's in from the of million, offset XX%

increased a mix scale.Selling sales NIAGEN as to and with and up which TRU basis levels year as sales to attributable largely to improved XX.X% benefits legal XX.X% net expense from higher driver sales, shift last administrative and XX%, XXXX more decreased the XX% XXXX, expense customer spend of mix aligned points driven percentage expense. quarter marketing in well XXX the our requires as and from of fourth million, by we of the Excluding a by of marketing as began in year.Gross lower quarter compared XXX in margins economies sales.As of XX.X% investment compared low from the points and to general this Nestle a largely full NIAGEN business the scale NIAGEN reported, partner to onetime by for quarter, year fourth than growth $X.X were royalty prior to ingredient had basis

higher improved marketing were as across loss by investments.Moving our sales cash higher offset by slightly the flow. initiatives optimize million the year-over-year operating our spending sheet Finally, to $X.X to organization and balance and

ended sheet balance We in with debt. million remains strong. Our and the cash quarter $XX.X no

full from of XXXX, with positive The in cash driven working prepaid million year accrued capital by improvements difference For and this in prior a impacts changes loss by our cash our $X.X $XX.X inventories working paired and increases other operations the changes versus was net capital. trade provided million in driven in net of and use payable. by was accounts year.The expenses and in assets, in receivables, were reductions year

the optimize such to invest XXXX our for to benefit release, earnings anticipate on capital drivers as working inventory, year key the we with do the in continue scale full as our of provided metrics key details we in outlook we P&L not similar presentation. a press we XXXX While slide along have business.Lastly,

and partners, to new and has new outlook established R&D product relates continued growth seen last XXXX in growth the XX% our through commercialization. that year launches.Over to the initiatives the upside XXXX.This opportunities channels e-commerce our compared company partnerships. growth rate to business full net revenue close new assumes year, It we sales, expect a through in are also As higher invested assumes with of it

continue are absolute our were Further, selling enter slightly will percentage up, marketing revenue be potential year-over-year optimize on plans and in to stable the optimization in overall influencer market we launch, and that in new customer as improve as during chain expect launch our we continue R&D marketing cost in that NAD plan that the expense There along for time, investments. resources is and to execute supply we are build to to hold benefit anticipate dollars, we development, gross net market we as estimated and revenue new in potential including invest as and our future to that on we place scale. launches, expect savings innovations building of e-commerce digital remain other outlook. applications sales.We that in in strategies acquisition and are growth internal up such, efforts around increase some year-over-year pursue As in but uses. confident the new team.We and invest still we investing which verticals.We in focused but we XXXX from will new year-over-year will will further categories our put market precursor long-term with a launches including timing marketing ramp our uncertainty more At from and close new same believe margin

We expect will in reported G&A expect investments we new year-over-year, $X.X years.Finally, that current increase trajectory more market million recent million anticipated meaningful be and driven by this infrastructure in to than growth launches. our $X.X be support to up to

cash As Accordingly, of ramp our not will to half launches. will this quarterly of in highest the expect highest we quarter in confident do first recorded year year ramp discipline to the continue these moderate.Furthermore, remain first to do include while year. business third for breakeven, revenues been first our second of XXXX with of approach this expect for the and and XXXX, operate will and flow the be the in investments have revenue anticipate bottom our the XXXX are XXXX top in the quarter we investments that outlook of while prepare we half. consistently line. will R&D we stronger same in At a to R&D we new disciplined time, our Since financial particularly the areas.We full to in revenue.We quarter the managing always, heavier approximately scaling investments,

reshaping also past as these and XX CFO, partnerships and significant the incredibly growth. of I'm we revenue increasingly cultivating are scale.In made new driving we impressed by promising time the in about proud actively impact accelerated summary, objectives, While recently of ourselves efficient passion on strides are the the optimistic months and endeavors secured launches by ] into will reflect have Though leaner, while to experienced have full our more a and and initiatives ChromaDex I promising company financial certain a as deals, unwavering we delivered consistently team. dedication ongoing organization our immediate XXXX.[ partnerships. on our focused new business shown We for delays, the I'm positioning take successfully

for new questions. ahead, as investors are Looking from we we innovation to see standard excited position are meaningful now take gold ChromaDex, ready further this solidifying company year.Operator, the our NAD to

Operator

[Operator the line question Instructions] with Ladenburg of Our first from comes Thalmann. Jeffrey Cohen

Jeffrey Cohen

So us you existing and I there, walk customers the out PRO and profile please? and TRU new seeing what little guess, dig a existing and firstly a customers for bit the you're perhaps margin NIAGEN for from give little from customers new customers, us, into landscape, conversions and flavor through can customers us

Robert Fried

dosage. that of have a conducted Well, have gram as dosage X,XXX been at milligram most X,XXX studies the been -- know, you

requests we So sell from many at the years had to that wanted dose comparable us over level. consumers who

and put us those weeks' customers. by in out of what marketplace, sold So is actually customers time.Now brand that out and the to to this in we formulation, it in create surprise X I decided November, new it took were believe, many we

in. got We think, upgrade from January, an out, to it I to comparable that it, the new expected supply or be December? the race customers to getting to studies. was dosage was existing getting that in We We

Brianna Gerber

ago, of yes. weeks couple A

Robert Fried

sold had we had right? it one, been now second the weeks third X one, first in weeks, ago, third -- last the out it's X a also That weeks. SKU. That with in in we the We see November, now think, out And of our -- January. we I one #X right came or December couple was our then in

which, consumers seeing we've the appears Brianna the shown question. So also but not be on margin safe. higher know, efficacious, defer that more dose, it benefits to as you of to I'll the our are only

Brianna Gerber

is price basis, NIAGEN. idea on upgrade are The per behind the it more a margins take lower a Gross -- equivalent slightly consumers idea dosage similar. to is Sure. but to

profit So I'd slightly profile for it's still good gross encourage say we very as maybe margin lower and similar, us, trade-ups. a

Jeffrey Cohen

And and of couple of to your that talk some then a partners. about talk trends comments also interest? of seeing, their of sell-through on Watson's the and with some on a about regard areas follow-up Nestle? perhaps Perhaps you're as Any

Robert Fried

Sure.

been us And most be for partner if interested Hong expanding As many It the of the It's one to now. relationship. years are important in Watson's you continues also in Watson's in for Kong. SKUs know, not the Singapore. chain single and extremely has an they most, in excellent Macau the

NIAGEN having with a a of product.But and added other also have late, to There's couple immune verticals other We into of our SKUs. expanding Watson's TRU TRU been with NIAGEN them. Beauty product, beginning they're sell about we've meetings

have expectations even in ] business of ChromaDex, So it's we have in that partner, been Watson's a tent pole the -- certainly partner. some interesting as XXXX, steady expansion and consistent partner, an but by a within with important really we'll truly XXXX, [ a opportunities the

Operator

of with question Mitch Pinheiro Sturdivant the next from comes line Our Company. &

Mitchell Pinheiro

my and first sales question just I around guess guidance. is guidance

curious, are either precursors, partners that these like we or expect going -- this mostly products XX% maybe when be that. ingredients? visibility to I or I'm -- So own new partners. are And the products, we should guess have some you've in new greater your in than said you Or able guidance, be to included of BXB you thing? you assumed other be in ingredient the decent to type guidance, say new to obviously, new in

Robert Fried

verticals robust the in a distribution know, at brands nicotinamide partners.And wholesale to precursors, brand. But deep chloride, also good, of What of to some when of business which stability way, the position, ChromaDex separate. with water nicotinamide not NAD. aqueous you, developed It's have other of exposed international where are some in platform we've And pursue you long portfolio.As and to therefore, certain an different our and just be countries the difficulties is riboside, nicotinamide approvals, also time, vertical, you or ingredient any nicotinamide have experienced we thank vast probably it's time, attributes expertise. harmful Well, different BXB other own because for to And really we -- sensitivity riboside is regulatory testing, of interesting as in this some our period supply have its but area testing less we've well-developed U.S. portfolio significant a well. the and a know, get you in of and to about those we any Mitch. more have precursors is efficacy own liquid. to a nicotinamide less that to a testing, is conducive water, all for we as have consumer it were endeavored know other when other riboside, might ribose our mentioned, efficacious. consumer but into addition, a and brand of same but tends solution ChromaDex's verticals.But Certain claims, safety not to to them to because as other -- our we but but it's riboside and exposed to require other precursors if

get going approvals, ChromaDex of lot business. that Well, takes indeed, it space in race supplement no it that.So claims. we a that's the time or mislabel do new are market the the to still alluded past believe make products believe testing that that with there obviously care in reason and it's of regulatory particular to time. if we've no any take and to why one few into dietary of. to the healthcare be very false late years. We over just it's even do taken the take doesn't several there And but on we way understand worked I to in But is have to long recognize vertical, Brianna that I some close. details close, are We and of it's a Now a does things need it is companies time, going because are very right.

our details control. Some not of those are within

year. projections, would further, this cake and want We the that's those our get with. in projections yet in we though, detail still would about quite even close talk we really partners it delay agencies or that were regulatory this to interact something And hear close, okay. for they're of happen enough there.Yes, I but We what about, conservative bake need further did making. not have if We it's if that projections would to but that it into it's for to that we're from into us launch the impact yes, is, don't there. believe

Mitchell Pinheiro

sort then follow-up that. And of a to

aside So business similar? impact ], be more then would that of and that Would efficiency to a to support something but that related in marketing And be Is to your launch -- an spending could for e-commerce margins improve. new model the on sales should the margins this continues expect [ marketing e-commerce sort negatively? business XXXX? you in we

Robert Fried

including company, for of that expenses marketing see increase for prepare and some going I But it meaningful XXXX expect the the entire a to we line as to do the you're first this quarter expect launch. an or impact in efficiency. for even I have year, on bottom marketing expenses R&D in do overall, margins not

Mitchell Pinheiro

expect marketing what... efficiency better So you're should current the or we the rate year, at to is comfortable in continue coming --

Robert Fried

for not But quarter. first necessarily the

Brianna Gerber

efficiency on reduced e-commerce dramatically since we quarter consistent the XXXX. fairly marketing seen of business in the we've Yes, third

stable. last are be full is in outlook our for that seen and homepage Amazon that play the other to consistently we've year, the of investments. selling from aside overall, since including overall year investments, these and then, And then quarter. the Rob's business, point, percentage e-commerce marketing a as So the some sales, takeover first out will fairly But there

Operator

Sean the of question comes with MKM. line Our McGowan next from ROTH

Sean McGowan

upside like for draw that be ingredients more my looks than that? deducing we expectations from to And going on anyway, in expectations and It quarter forward? what Am can in seems in consumer. margin in I the X correct gross revenue based the

Brianna Gerber

is Sean, consumer always But quarter-to-quarter, what in that. say full The mid-XXs. on a back I'd there's the you the some in the mid-XXs. basis, ingredient is is lumpiness step in products year if

our see variable. blend skew outlook, which And XX% we'll do bit.We slight improvement to will we on this better full said so year than margin a think, we a in nice gross you little basis it as sometimes are little e-commerce, The more mix leverage business a year. bit leveraging the including costs, are other that as business we supply a that Whereas shipping for some investment ingredient about there's think some in fixed the a get NIAGEN here. things teams and on chain our if

quarter, about a the right same is your So of on I think but on more I the full think take it year, continuation.

Sean McGowan

-- the permanent shouldn't in look the that we fourth a in up we're and So an quarter, gross of I at XX%. sort in that like step profit expect anomaly, in -- a that not ingredients it gross segment? like margin looked is Is like almost

Brianna Gerber

the ingredient I'd NIAGEN to -- lumpy because that ingredient be quarter-to-quarter. of can -- look sales are timing partners, at yes, sales

it I on and at full a that look basis it So way. about think year

Sean McGowan

a or better? a all, closer And trying and above when say mean, about range that then point this want the it to of wide it'll to XX%? be I about is to Or bracket that are potentially meaningfully extent little what you like that -- just outcomes -- at should you talking maybe there's bit I'm we just be bit. starting to XX%. talk a possible the

Robert Fried

to So part of projections projections. that something it's that's this we Obviously, difficult in been that in very has we're make think But conservative our with to yet. market launch about. new talking the product on we've not do

know poorly, will that yet So think if XXXX. very still it we We we don't we beat know. that does

Sean McGowan

rate? Do sales you in total mean in it or beat beat it growth

Robert Fried

Beat it in growth rate.

Operator

of Capital Our next with Matt the question from Tieton comes line Dhane Management.

Matthew Dhane

know have you to through ask folks going there. I website. truniagen.com an want process optimization the did about I been

underperforming been You last the has said year. it over

from that at So the optimizing and journey website what just curious you're it? to in starting of where and see you're improving

Robert Fried

NIAGEN, on cycle. TRU like below we'd after reorder first particularly to strong return always be. but We is improved it what it's with ad the spend, still the Retention the pretty have

the orders. some is work our return dollars. have very we good So value still for new-to-brand But to long-term website still the improve on advertising do to

Matthew Dhane

you is Is going in to in or dialed than longer X, here that? take it quarter to the have Or Rob? next that expect something

Robert Fried

quarter. more individuals based and algorithmic It's improving is made their return that's companies, difficult alone optimization This better on seeing By it's is improving or not We're in social a to made for preferences. pervasive process. iOS companies iterative this media the companies the way, particularly we're each a process. it target process. personal throughout process an It and changes since e-commerce retarget on spend in our advertising its

couple spend upfront. more to So for marketing over it's to last been -- companies years of challenging convert is digital still, marketing relative But many the efficiently dollars spend their our customers think Each get be I better to to enough. still will quarter still better, continue But high. better. and good getting will it's next and not it's new-to-brand is quarter too

Matthew Dhane

also launch to did want I several that referenced you've the question one additional around ask product this new during call. times

to your in you're I marketing know here that be today, here around product here in first expectation that time? of launched Is a is referenced R&D sit going up ramping Is that and new this really the at the fair is in you you still As up on be spending going QX. it Or to this point air? half that 'XX? expectation in

Robert Fried

say it's would I possible.

Operator

to closing There further like now this over at call to remarks. Gerber time. questions are for would the Brianna I no turn

Brianna Gerber

everyone, call ID There replay your of number XXXXXXX. today. beginning Thank ]. replay will Mandeep ChromaDex. us joining of and [ be The today at the you, replay Thank support is for continued p.m. X-XXX-XXX-XXXX, a is and you, for Time X:XX Eastern this

Operator

today's This concludes call.

You may now disconnect.

ChromaDex (CDXC) 6 Mar 242023 Q4 Earnings call transcript